Summary
Diabetic individuals frequently have platelet hyperaggregability and increased thromboxane (TXB2) production. To evaluate whether improvement of metabolic control or changes in fatty acid composition of serum lipids might alter thromboxane (TXB2) formation and platelet function, we followed up 25 newly diagnosed type 2 diabetics without angiopathy for about 6 months. Improvement of metabolic control (HbA1, fell from 12.0±0.3 to 9.0±0.3%;p<0.01) was associated with significant decrease in total cholesterol, triglycerides, and ratios of total cholesterol/HDL-cholesterol and LDL-cholesterol/HDL-cholesterol. Palmitic acid of phospholipids decreased significantly, whereas eicosapentaenoic acid increased. Regardless of this, the ADP-induced platelet aggregability and sensitivity were not altered. There was no effect whatever on the TXB2 synthesis capacity of clotting whole blood (204.9±25.0 vs 222.8±32.0 ng/ml) over 6 months of treatment. Platelet aggregability and TXB2 formation were not correlated to the degree of metabolic control, nor were there any correlations to serum lipids and their fatty acid composition. Thus, we are tempted to speculate that glucose metabolism in diabetes itself does not affect platelet aggregation or TXB2 formation in type 2 diabetes mellitus.
Similar content being viewed by others
Abbreviations
- TXB2 :
-
Thromboxane B2
- HbA1 :
-
Glycosylated hemoglobin A1
- HDL:
-
High density lipoproteins
- LDL:
-
Low density lipoproteins
- ADP:
-
Adenosine diphosphate
- P/S Ratio:
-
Polyunsaturated fatty acids/saturated fatty acids ratio
- ECG:
-
Electrocorticogram
- TAC 50:
-
Threshold aggregating concentration eliciting 50% of maximal response
References
Aleyassin H, Gardiner RJ, Tonks DB, Koch P (1980) Glycosylated hemoglobin in diabetes mellitus: correlations with fasting plasma glucose, serum lipids and glucosuria. Diabetes Care 3:508–514
Arzneibuch der DDR (1983) Diagnostische Laboratoriumsmethoden. Akademie-Verlag, Berlin
Bern MM (1978) Platelet function in diabetes mellitus. Diabetes 27:342–350
Born GVR, Cross MJ (1963) The aggregation of platelets. J Physiol 168:178–195
Butkus A, Shirey EK, Schumacher OP (1982) Thromboxane biosynthesis in platelets of diabetic and coronary artery diseased patients. Artery 11:238–251
Carter AJ, Jones EW (1986) The effect of the degree of diabetic control on thromboxane synthesis in clotted whole blood. 41:137–141
D'Angelo A, Micossi P, Mnnucci PM, Garimberti B, Franchi F, Pozza G (1984) Increased production of platelet thromboxane B2 in non-insulin-dependent diabetes. Relationship to vascular complications. Europ J Clin Invest 14:83–86
Davis TME, Brown E, Turner RC (1985) Platelet sensitivity in vitro to adenosine-5-diphosphate and prostacyclin and diabetic retinopathy. Diabetologia 28:274–276
Ewald U, Kobbah M, Tuvemo M (1983) Increased platelet aggregability in diabetic children: relation to serum lipid and fatty acid composition. Diabetologia 25:382–385
Friedewald WT, Levy KJ, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499–502
Gisinger C, Schernthaner G (1986) Increased platelet malondialdehyde, but normal platelet sensitivity to adenosine-5-diphosphate and prostacyclin in well-controlled type 1 diabetics without vascular complications. Diabetes Res 3:40–44c
Gnauck G, Stolz P, Honigmann G, Singer P (1973) Die gaschromatographische Analyse der Lipid-Fettsäuren in Serum und Organgewebe. Z Med Lab Techn 14:15–23
Halushka PV, Rogers RC, Loadholdt CB, Colwell JA (1981) Increased thromboxane synthesis in diabetes mellitus. J Clin Med 97:87–96
Hendra T, Betteridge DJ (1989) Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids (Reviews) 35:197–212
Pecoraro RE, Graf RJ, Halter JB, Beiter H, Porte D (1979) Comparison of a colorimetric assay for glycosylated hemoglobin with ion-exchange chromatography. Diabetes 28:1120–1125
Huupponen RK, Viikari JS, Saarimaa H (1984) Correlation of serum lipids with diabetes control in sulfonylurea-treated diabetic patients. Diabetes Care 7:575–578
Moore RA, Oppert S, Eaton P, Mann JI (1977) Triglyceride fatty acids confirm a change in dietary fat. Clin Endocrinol 177:143–149
Nell A, Kment G, Matejka M, Porteder H, Peskar BA, Sinzinger H (1988) Abnahme, Präparation und Aufbewahrung menschlichen Plasmas zur radioimmunologischen Bestimmung von Thromboxan B2. Wien Klin Wochenschr 100:700–706
Ratzmann KP, Ilius A (1986) Erfahrungen mit einem strukturierten Diaetschulungsprogramm. Z Klin Med 41:289–291
Ratzmann KP, Schimke E (1987) Verhalten von Fettsäuremustern in Serumlipiden bei Typ I Diabetikern während intensivierter konventioneller Insulintherapie. Dtsch Z Verdau Stoffwechselkr 47:326–330
Ratzmann KP, Raskovic M, Thoelke H (1989) Bedeutung von Proteinurie und Hypertonie für die Prognose des Typ I-Diabetes. Dtsch Med Wochenschr 114:1311–1315
Takahasi R, Shiraki M, Morita I, Murota S, Orimo H (1985) Platelet synthesising activity in non-insulin-dependent diabetes: correlation with diabetic retinopathy and diabetic treatment. Prostaglandins Leukot Med 17:149–158
Taube C, Hoffmann P, Foerster W (1982) Enhanced thromboxane production in the aorta of spontaneously hypertensive rats in vitro. Prostaglandins Leukot Med 9:411–415
Tilvis RS, Miettinen IA (1985) Fatty acid composition of serum lipids, erythrocytes and platelets in insulin-dependent diabetic women. J Clin Endocrinol Metab 61:741–745
WHO Study Group (1985) Diabetes Mellitus (Technical Report Series No. 727). World Health Organization, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratzmann, K.P., Schimke, E., Beitz, A. et al. Thromboxane production and platelet aggregation in type 2 diabetes mellitus without vascular complications. Klin Wochenschr 69, 652–656 (1991). https://doi.org/10.1007/BF01649426
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01649426